Sernova Corp T.SVA

I see $20 per stock

[WEST-VAN-INVESTOR]

1.6m type 1 cases in USA x $10000 avg cost per yr. x 25% of the market x 10% profit  margin = $400 mil prof a year.  

$400m prof per year / 208 m shares = $2.  Prof per share per yr.   

10% return.    I see $20 stock.

[fogduckker]

But you are only talking about one application there could be many more sort of like valuing Amazon back in the day based on revenues from book sales

[MedStocks2]

exactly fog. Cearly West Van knows nothing about this company. Everyone here realizes that with the immune tech, this will fly through approval for all type 1 and type 2 insulinlin dependent diabetics. Add to that the list of diseases that can be moderated or cured through cell therapy.

[WEST-VAN-INVESTOR]

https://www.cbc.ca/amp/1.5079939

[Redbaron2211]

human donor islets @ 4.2k transplants can bring in 350-400 mil revenue.  Using iPSC islets this revenue blows up to 30 Billion for just TD1 in USA, Europe, China and Japan.   15% profit margin/earnings is 4.5 Billion.  Use a modest P/E ratio of 20 and you can imagine why big pharma wants a piece and why we have yet to see any insider sales.     

[WEST-VAN-INVESTOR]

As I said.  Here are my numbers.   If you have better numbers please provide.    The numbers say $20 stock.   1.6m type 1 cases in USA x $10000 avg cost per yr. x 25% of the market x 10% profit  margin = $400 mil prof a year.   $400m prof per year / 208 m shares = $2.  Prof per share per yr.    10% return.    I see $20 stock

[cowjazz]

This post has been removed in accordance with Community Policy

[MedStocks2]

West Van you are like the guy who invented the wheel and could not understand anything more than it was fun to watch it roll down hill. Clearly you don't understand the regen market let alone the company. Most everyone here, except you has already done the homework at a minimum on the indications currently listed by the company.

[MoneyMouth]

He probably meant to say "at least" $20 dollars. You dont gotta jump down his throat man, we are all on the same team

[MedStocks2]

whatever MM. People in this board have been discussing the potential applications and breadth of the regen market. I have little patience for someone asking me for my numbers when they haven't even been following the discussions over time or even stopped to look at the market value of the potential indications.